Arovella Therapeutics (ALA.AX) Earnings Analysis
Arovella Therapeutics (ALA.AX) next reports earnings on 2026-09-02, consensus EPS -0.009 AUD. Last quarter (2026-02-18) it beat with EPS -0.0016 AUD vs -0.004 AUD est (+60%). It has beaten estimates in 3/3 recent quarters (100%). Trailing P/E -9.14.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ALA.AX next report earnings?
| Next earnings date | 2026-09-02 |
|---|---|
| Consensus EPS estimate | -0.009 AUD |
| Revenue estimate | n/a |
ALA.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-18 | -0.0016 AUD | -0.004 AUD | +60% | Beat |
| 2025-08-22 | -0.0054 AUD | -0.006 AUD | +10% | Beat |
| 2025-02-26 | -0.0014 AUD | -0.002 AUD | +30% | Beat |
| 2024-08-22 | -0.0048 AUD | n/a | n/a | n/a |
Beat rate: 3/3 (100%) over reported quarters with consensus data.
ALA.AX valuation and analyst view
| Trailing P/E | -9.14 |
|---|---|
| Trailing EPS | -0.00663 AUD |
| Price / book | 4.05 |
| Dividend yield | 0.00% |
| Market cap | 0.08B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Arovella Therapeutics (ALA.AX)'s next earnings date?
Arovella Therapeutics is next scheduled to report on 2026-09-02, with a consensus EPS estimate of -0.009 AUD.
Did ALA.AX beat earnings last quarter?
In its 2026-02-18 report, ALA.AX posted EPS of -0.0016 AUD versus a -0.004 AUD estimate — a beat of 60%.
What is ALA.AX's earnings track record?
Over the last 3 reported quarters with consensus data, ALA.AX beat estimates 3 times (100%).
What is ALA.AX's current P/E ratio and EPS?
ALA.AX trades at a trailing P/E of -9.14 on trailing EPS of -0.006627055957234982 AUD.
What do analysts rate ALA.AX?
ALA.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.